Rechercher des projets européens

29 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment (IMPACTT)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

"Cystic Fibrosis (CF) is a chronically debilitating and life threatening medical condition. Respiratory insufficiency and complications of chronic lung infection lead to long term reduction in quality of life and health and even to premature death. Chronic bacterial infections with Pseudomonas aeruginosa (PA), Staphylococcus aureus and Haemophilus influezae are typical for CF and repeated courses ...
Voir le projet

 10

 TERMINÉ 

European Medicines Research Training Network (EMTRAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Voir le projet

 32

 TERMINÉ 

NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE (TRANSEURO)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2016,

There are currently no cures for Parkinson's disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for yea ...
Voir le projet

 15

 TERMINÉ 

European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults (ENS@T-CANCER)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,

Among patients with adrenal masses Adrenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH) are found with a low incidence but very unfavorable prognosis. Due to this poor clinical outcome, concomitant hormone dysregulation and limited treatment options the two cancer entities severely impact on affected patients. However, the rarity of the tumors also impedes clinical studies which ar ...
Voir le projet

 17

 TERMINÉ 

Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency (CELL-PID)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity and high risk of cancer. Treatment entails hematopoietic stem cell (HSC) transplantation from allogeneic donors, however in the absence of an HLA compatible donor, HSCT outcome is limited by delayed or suboptimal reconstitution and complications. SCID-X1 and ...
Voir le projet

 20

 TERMINÉ 

Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use ...
Voir le projet

 17

 TERMINÉ 

Beta Cell Therapy in Diabetes (BETACELLTHERAPY)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,

Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage ...
Voir le projet

 18

 TERMINÉ 

A systems biology approach to dissect cilia function and its disruption in human genetic disease (SYSCILIA)

Date du début: 1 juin 2010, Date de fin: 31 mai 2015,

AIM: To identify the molecular mechanisms characterizing cilium function, and the discrete perturbations associated with dysfunction caused by mutations in inherited ciliopathies, applying a systems biology approach. BACKGROUND: Cilia are microtubule-based, centriole-derived projections from the cell surface. They transduce extracellular signals and regulate key processes in which signals of the e ...
Voir le projet

 17

 TERMINÉ 

Suicidality: Treatment Occurring in Paediatrics (STOP)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,

The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Rela ...
Voir le projet

 19

 TERMINÉ 

Genetic and Epigenetic Networks in Cognitive Dysfunction (GENCODYS)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2015,

Mutations in about 400 different genes have been associated with Cognitive Disorders (CD), such as mental retardation, autism, neurodegenerative disorders, and psychiatric disorders. Whereas CD impose a major medical and socio-economical problem, there are no systematic studies that aim to provide insight into common mechanisms in CD. We propose a systems biology approach to gain insight into comm ...
Voir le projet

 15

 TERMINÉ 

Paediatric European Risperidone Studies (PERS)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2015,

"Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in ado ...
Voir le projet

 22

 TERMINÉ 

Treatment of NEonatal seizures with Medication Off-patent: evaluation of efficacy and safety of bumetanide (NEMO)

Date du début: 1 oct. 2009, Date de fin: 31 mars 2015,

Neonatal hypoxic ischaemic encephalopathy (HIE) occurs in 2-3/1000 live births and is a major cause of both acute mortality and long-term neurodisability. Seizures are the hallmark of HIE. The clinical and electrographic seizure burden in babies with HIE can be considerable and is often not reduced by current antiepileptic drugs. Phenobarbitone remains the first line drug for neonatal seizures des ...
Voir le projet

 15

 TERMINÉ 

European Consortium for Communicating Stem Cell Research (EuroStemCell)

Date du début: 1 mars 2010, Date de fin: 28 févr. 2015,

The European Consortium for Communicating Stem Cell Research, EUROSTEMCELL, brings together the major current FP6 and FP7 stem cell projects, the European Clinical Research Infrastructure Network, and four internationally recognized European stem cell centres to develop a comprehensive, coordinated platform for collation, dissemination and archiving of information on stem cell biology and regenera ...
Voir le projet

 11

 TERMINÉ 

International Network for Early Childhood Health Development (INECHD)

Date du début: 1 mars 2011, Date de fin: 28 févr. 2015,

The general aim of the INECHD is to strengthen collaborative interdisciplinary research and knowledge transfer on early childhood health development and well-being. Recent research from numerous disciplines clearly highlights the importance of early childhood development (pregnancy to school entry) for the prevention of long term health and social adjustment problems. Large interdisciplinary-inter ...
Voir le projet

 2

 TERMINÉ 

Improvement of current and development of new vaccines for theileriosis and babesios of small ruminants (PIROVAC)

Date du début: 1 avr. 2010, Date de fin: 30 sept. 2014,

The proposal deals with the establishment of control measures for two major tick-borne diseases of small ruminants: theileriosis caused by Theileria lestoquardi and T. uilenbergi and babesiosis caused by Babesia ovis. The research programme aims at improving existing and producing new attenuated vaccines, designing subunit vaccines and capability building. To achieve these goals the proposal will ...
Voir le projet

 15

 TERMINÉ 

Role of Skeletal Stem Cells in Bone Repair (Skeletal Stem Cells)

Date du début: 1 sept. 2010, Date de fin: 31 août 2014,

It is estimated that 2% of the population sustain fractures annually, which in Europe corresponds to approximately 15 millions fractures and in France 1 million fractures. Although bone exhibits strong regenerative properties, delayed unions and non-unions still occur at a frequency of 5 to 10% in all skeletal injuries leading to patient disability and high societal cost. Bone repair is dependent ...
Voir le projet

 1

 TERMINÉ 

"Spontaneous clearance in Patients acutely infected with HCV - Immune profiling, Novel biomarkers and X-omics approaches" (SPHINX)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,

"The proposed project aims to identify novel biomarkers and provide new insight into the mechanisms of spontaneous clearance of hepatitis C virus (HCV) during the early stages of acute infection. Indeed hepatitis C is a major public health problem with high incidence in regions such as Egypt and other Mediterranean Partner Countries (MPCs). Our current application follows from an FP5 project entit ...
Voir le projet

 10

 TERMINÉ 

Protease signaling in development and disease (Protease Signaling)

Date du début: 1 déc. 2009, Date de fin: 30 nov. 2013,

Protease- activated receptors (PARs) comprise a family of four G-protein coupled receptors that mediate cellular responses to proteases. PARs were identified in a search for the platelet receptor for the coagulation protease thrombin. Mouse deficiency models later established critical roles for PARs in hemostasis and thrombosis and in vascular development, yet unexplained functions ascribed to pro ...
Voir le projet

 1

 TERMINÉ 

Predicting antibiotic resistance (PAR)

Date du début: 1 avr. 2010, Date de fin: 31 mars 2013,

"The aim of this proposal is to describe and predict the dynamics of antibiotic resistance development at the level of the drug target, the microbe and the host. That is, we want to generate the knowledge required to be able to connect resistance mechanism --> bacterial physiology and fitness --> bacterial survival within a host --> bacterial spread between hosts. To achieve this goal we will deve ...
Voir le projet

 12

 TERMINÉ 

Impact of the chromatin environment on the CTG repeat instability involved in myotonic dystrophy type 1 (DM and Chromatin)

Date du début: 1 sept. 2010, Date de fin: 31 août 2012,

Since the identification of unstable trinucleotide repeats (TNRs) as the genetic cause of human neurological diseases, many studies have tried to unravel the mechanisms of repeat expansion. MSH2 and MSH3, DNA mismatch repair proteins, modify expansion in transgenic mice. Circumstantial evidence suggests that cis-elements surrounding the repeats modulate their instability. However, a detailed analy ...
Voir le projet

 1

 TERMINÉ 

Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis (HOMITB)

Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,

"Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt clinical disease, do so within two years of primary infection. The remaining half of the TB patients, develop clinical disease later, owing to “reactivation” of pulmonary TB. Of importance, it is not understood why only 10% infected individuals develop activ ...
Voir le projet

 9

 TERMINÉ 

Molecular and structural analysis of A20 in the modulation of apoptosis: anti-inflammatory potential in vasculitis (A20APOPTOSIS)

Date du début: 1 avr. 2008, Date de fin: 31 mars 2012,

"The ubiquitin editing protein A20, a novel 90kDa zinc-finger protein has an universal anti-inflammatory activity by inhibiting NF-kappaB activation. In endothelial cells, the induction of A20 by inflammatory stimuli renders cells resistant to apoptosis. However, A20 can have pro-apoptotic activities in other cell types. We will focus on the respective role of A20 in both endothelial cells and neu ...
Voir le projet

 1

 TERMINÉ 

Cultivated Adult Stem Cells as Alternative for Damaged tissue (CASCADE)

Date du début: 1 janv. 2009, Date de fin: 31 déc. 2011,

"Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The objective of CASCADE is to provide the European Community with unique expertise which focuses on the GMP production of mesenchymal stem cells (MSC) and their use in treating skin and corneal wounds, so that quality and safety criteria are paramount and match the ...
Voir le projet

 16

 TERMINÉ 

"Mathematical modelling of beta-catenin and ras signalling in liver and its impact on proliferation, tissue organization and formation of hepatocellular carcinomas" (CANCERSYS)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2011,

"The goal of the CANCERSYS project is to establish a multi-scale model for two major signalling pathways involved in the formation of hepatocellular carcinoma, the beta-catenin and ras signalling pathways. Integrative studies linking measurements in primary heptocytes with effects at the organ level will address the impact of these signalling networks on proliferation, tissue organization and form ...
Voir le projet

 10

 TERMINÉ 

Global regulation in Mycobacterium: Role of Lsr2 (MYCO-REG)

Date du début: 15 sept. 2009, Date de fin: 14 sept. 2011,

"This proposal aims at understanding the role of Lsr2 in the global regulation of the mycobacterial cell wall homeostasis, a critical attribute of their virulence. Mycobacteria are Gram-positive bacteria that are involved in a number of human (tuberculosis, leprosy, Buruli ulcer) and animal diseases (Johne’s disease in ruminanst, fish tuberculosis in aquaculture), in both developing and developed ...
Voir le projet

 1

 TERMINÉ 

"DIAbetes type 1 PRediction, Early Pathogenesis and Prevention" (DIAPREPP)

Date du début: 1 avr. 2008, Date de fin: 31 août 2011,

"The earliest currently identifiable process in the pathogenesis of type 1 diabetes (T1D) is the development of autoimmunity to islet beta cells in the form of autoantibodies. Hindering attempts to prevent autoimmune T1D, the aetiology and pathogenesis of the islet auto-immunization, including whether it is preceded by metabolic abnormalities and cell-mediated autoimmunity, is still poorly underst ...
Voir le projet

 12

 TERMINÉ 

European initiative to improve knowledge, treatment and survival of haemophagocytic syndromes in children (CureHLH)

Date du début: 1 juin 2008, Date de fin: 31 mai 2011,

Haemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening inherited immune disorder of early childhood characterised by an uncontrolled immune response. Three disease causing genes have been identified in about half of the patients. Diagnosis is difficult, pathophysiology poorly understood, and treatment unsatisfactory with about 40% of the children dying from treatment failure or t ...
Voir le projet

 9

 TERMINÉ 

The Pathophysiology and Natural Course of Patients with Primary Antibody Deficiencies (PAD) (EURO-PADnet)

Date du début: 1 mai 2008, Date de fin: 30 avr. 2011,

This medium-sized collaborative project will document and monitor the natural course and study the pathophysiology of Primary Antibody Deficiencies (PAD). PADs are rare inborn errors of the immune system with an estimated incidence of
Voir le projet

 13

 TERMINÉ 

Impact on Clinical Research of European Legislation (ICREL)

Date du début: 1 janv. 2008, Date de fin: 31 déc. 2008,

"This project aims primarily at analysing and measuring the impact of Directive 2001/20/EC (Clinical Trials Directive, CTD) and related legislation on the industry and academic clinical research with medicinal products but also on their impact on clinical research in the broader sense. This initiative fits with the need to provide evidence for a potential reconsideration of certain aspects of the ...
Voir le projet

 6